Navigation Links
Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
Date:9/13/2009

PRINCETON, N.J. and SAN DIEGO, Sept. 13 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR. Cytotoxicity (cell number, morphology) was also assessed. The average 50% inhibitory concentration (IC50) for TBR-652 was 0.99+0.19 (range 0.72-1.43) nM. Weak synergy was seen in combinations of TBR-652 with LPV (IC50 26.90-40.27 nM), ATV (IC50 57.66-78.89 nM), DRV (IC50 2.12-2.78 nM) and ETV (IC50 71.77-83.35 nM). Additive effects were seen with TBR-652 plus TDF (IC50 10.66-11.13 nM) or RAL (IC50 29.66-103.72nM). Importantly, no antagonism and no cytoxicity were observed with any 2-drug combination at any concentration tested.

"These in vitro results provide evidence that combination regimens containing TBR-652 and one or more of these agents are possible and should be further evaluated in HIV-infected patients," said James Sapirstein, CEO.

These data were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 12-15, 2009 in San Francisco, California. The poster presentation can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    Tobira Therapeutics Inc.
    Antoinette Bobbitt Tobira Therapeutics, Inc.
    abobbitt@tobiratherapeutics.com
    Tel: 609-897-1102
    www.tobiratherapeutics.com

'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Tobira Therapeutics Inc. Receives US Patent for TBR-652
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing strategy drives 85% ... in consumable sales, quarter-over-quarter ... ), a leader in digital health and mobile health ... Monitoring System, an all-in-one diabetes meter, today announced continued ... smart diabetes management solution. In just ...
(Date:1/23/2017)... 2017 Research and Markets has announced the addition ... Product - Forecast to 2025" report to their offering. ... Report Highlights: ... to identify the investment opportunities Market forecasts till 2025, ... market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... NEW YORK , January 23, 2017 ... Biotech equities to see how they have fared at the close: ... BPMX), OvaScience Inc. (NASDAQ: OVAS ), and Regeneron Pharmaceuticals ... the NASDAQ, Biotechnology shares were relative laggards on Friday, January 20 ... can access our complimentary research reports on these stocks now at: ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In ... mysterious phenomenon is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is ... Beautiful Creation,” a Christian-based talk show located in Michigan. , “We need to ...
(Date:1/24/2017)... PA (PRWEB) , ... January 24, 2017 , ... ... breast implants, a new scientific article suggests that autologous fat grafting—taking ... for achieving larger breasts naturally, without breast implants. , Cosmetic Surgeon and ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
(Date:1/24/2017)... Texas (PRWEB) , ... January 23, 2017 , ... ... its presence in Texas with the acquisitions of two personal care service companies: ... in Texas City, Texas, effective January 1, 2017. , Well regarded in their ...
(Date:1/24/2017)... ... January 23, 2017 , ... Somnoware, ... plugin that allows sleep centers to automatically connect and initialize all their devices ... client browser plugin is quickly installed on first use and then monitors device ...
Breaking Medicine News(10 mins):